%PDF-1.4
%
34 0 obj
<>
endobj
31 0 obj
<>
endobj
91 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-24T11:59:13Z
2024-03-29T08:54:44-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T08:54:44-07:00
application/pdf
Heather
200738.april
uuid:57906018-1dd2-11b2-0a00-bc09275dc400
uuid:5790601b-1dd2-11b2-0a00-810000000000
endstream
endobj
20 0 obj
<>
endobj
21 0 obj
<>
endobj
35 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
13 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
113 0 obj
[117 0 R]
endobj
114 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(patients with systemic lupus erythematosus. J Rheumatol)Tj
0 Tw 0 -1.25 TD
(1993;20:661-5.)Tj
0.02499 Tw -2.175 -1.25 Td
[(31.)-875 (Petri M, Lakata C, Magder L, Goldman D. Ef)17.8 (fect of prednisone and)]TJ
-0.00011 Tc 2.175 -1.25 Td
(hydroxychloroquine on coronary artery disease risk factors in)Tj
0 Tc T*
[(systemic lupus erythematosus: a longitudinal data analysis. )54.8 (Am J)]TJ
T*
(Med 1994;96:254-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(32.)-875.1 (Kavanaugh )54.8 (A, )54.8 (Adams-Huet B, Jain R, Denke M, McFarlin J.)]TJ
2.175 -1.25 Td
[(Hydroxychloroquine ef)17.7 (fects on lipoprotein profiles \(the HELP)]TJ
0 Tc T*
[(trial\): )54.9 (A)-219.8 (double-blind, randomized, placebo-controlled, pilot study)]TJ
T*
(in patients with systemic lupus erythematosus. J Clin Rheumatol)Tj
0 Tw T*
(1997;3:3-8.)Tj
0.0249 Tw -2.175 -1.25 Td
[(33.)-875 (Rahman P)110.8 (,)0.1 ( Gladman DD, Urowitz MB, )36.8 (Y)111.1 (uen K, Hallett D, Bruce)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(IN. )17.7 (The cholesterol lowering ef)17.7 (fect of antimalarial drugs is)]TJ
0 Tc T*
(enhanced in patients with lupus taking corticosteroid drugs.)Tj
0.275 -1.25 Td
(J Rheumatol 1999;26:325-30.)Tj
-2.45 -1.25 Td
[(34.)-875 (T)69.8 (am LS, Li EK, Lam CW)91.8 (, )17.8 (T)69.8 (omlinson B. Hydroxychloroquine has)]TJ
2.175 -1.25 Td
[(no significant ef)17.8 (fect on lipids and apolipoproteins in Chinese)]TJ
T*
(systemic lupus erythematosus patients with mild or inactive)Tj
T*
(disease. Lupus 2000;9:413-6.)Tj
-2.175 -1.25 Td
[(35.)-875 (T)69.8 (am LS, Gladman DD, Hallett D, Rahman P)110.8 (,)0.1 ( Urowitz MB. Ef)17.8 (fect)]TJ
2.175 -1.25 Td
(of antimalarial agents on the fasting lipid profile in systemic lupus)Tj
T*
(erythematosus. J Rheumatol 2000;27:2142-5.)Tj
-2.175 -1.25 Td
[(36.)-875 (T)69.8 (an EM, Cohen )54.8 (AS, Fries JF)79.8 (, et al. )17.7 (The 1982 revised criteria for the)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(37.)-875.1 (Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH,)]TJ
0 Tc 2.175 -1.25 Td
(and the Committee on Prognosis Studies in SLE. Derivation of the)Tj
T*
[(SLEDAI. )54.9 (A)-219.8 (disease activity index for lupus patients. )54.9 (Arthritis)]TJ
T*
(Rheum 1992;35:630-40. )Tj
-2.175 -1.25 Td
[(38.)-875 (Siedel J, H\344gele EO, Ziegenhorn J, )17.8 (W)79.8 (ahlefeld )54.9 (A)80.1 (W)91.8 (. Reagent for the)]TJ
2.175 -1.25 Td
(enzymatic determination of serum total cholesterol with improved)Tj
T*
[(lipolytic ef)17.8 (ficiency)64.9 (. Clin Chem 1983;29:1075-80.)]TJ
-2.175 -1.25 Td
[(39.)-875 (Fossati P)110.8 (, Prencipe L. Serum triglycerides determined)]TJ
2.175 -1.25 Td
(colorimetrically with an enzyme that produces hydrogen peroxide.)Tj
T*
(Clin Chem 1982;28:2077-80.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(40.)-875.1 (W)79.7 (arnick GR, Cheung MC, )54.8 (Albers JJ. Comparison of current)]TJ
0 Tc 2.175 -1.25 Td
(methods for high-density lipoprotein cholesterol quantification.)Tj
T*
(Clin Chem 1979;25:596-604.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(41.)-875.1 (Friedewald )17.7 (WT)73.9 (, Levy RI, Fredrickson DS. Estimation of the)]TJ
0 Tc 2.175 -1.25 Td
(concentration of low-density lipoprotein cholesterol in plasma,)Tj
T*
(without use of the preparative ultracentrifuge. Clin Chem)Tj
0 Tw T*
(1972;18:499-502.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(42.)-875.1 (Munro R, Morrison E, McDonald )54.8 (AG, Hunter JA, Madhok R,)]TJ
0 Tc 2.175 -1.25 Td
[(Capell HA. Ef)17.8 (fect of disease modifying agents on the lipid profiles)]TJ
T*
[(of patients with rheumatoid arthritis. )54.9 (Ann Rheum Dis 1997;)]TJ
0 Tw T*
(56:374-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(43.)-875.1 (Zimmerman J, Fainaru M, Eisenber)17.7 (g S. )17.7 (The ef)17.7 (fects of prednisone)]TJ
0 Tc 2.175 -1.25 Td
(therapy on plasma lipoproteins and apolipoproteins: a prospective)Tj
T*
[(study)65 (. Metabolism 1984;33:521-6.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(44.)-875.1 (Ettinger )17.7 (WH, Klinefelter HF)79.7 (, Kwiterovitch PO. Ef)17.7 (fect of short-)]TJ
0 Tc 2.175 -1.25 Td
(term, low-dose corticosteroids on plasma lipoprotein lipids.)Tj
-0.00011 Tc T*
(Atherosclerosis 1987;63:167-72.)Tj
30.825 63.75 Td
[(45.)-875.1 (Castelli )17.7 (WP)110.7 (, Garrison RJ, )17.7 (W)39.7 (ilson PW)91.7 (, )54.8 (Abbot RD, Kalousdian S,)]TJ
0 Tc 2.175 -1.25 Td
[(Kannel )17.8 (WB. Incidence of coronary heart disease and lipoprotein)]TJ
T*
[(cholesterol levels. )17.7 (The Framingham Study)64.9 (. JAMA)-220.1 (1986;)]TJ
0 Tw T*
(256:2835-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(46.)-875.1 (Jacobs DR Jr)39.7 (, Mebane IL, Bangdiwala SI, Criqui MH, )17.7 (T)69.7 (yroler HA.)]TJ
0 Tc 2.175 -1.25 Td
(High density lipoprotein cholesterol as a predictor of cardiovascular)Tj
T*
(disease mortality in men and women: the follow-up study of the)Tj
T*
[(Lipid Research Clinics\222)-201 (Prevalence Study)64.9 (. )54.8 (Am J Epidemiol)]TJ
0 Tw T*
(1990;131:32-47.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(47.)-875.1 (Ettinger )17.7 (WH, Goldber)17.7 (g )54.8 (AP)110.8 (, )54.8 (Applebaum-Bowden D, Hazzard )17.7 (WR.)]TJ
0 Tc 2.175 -1.25 Td
[(Dyslipoproteinemia in systemic lupus erythematosus: Ef)17.8 (fect of)]TJ
T*
[(corticosteroids. )54.9 (Am J Med 1987;83:503-8.)]TJ
-2.175 -1.25 Td
[(48.)-875 (Ettinger )17.7 (WH Jr)39.8 (, Hazzard )17.7 (WR. Elevated apolipoprotein-B levels in)]TJ
2.175 -1.25 Td
(corticosteroid-treated patients with systemic lupus erythematosus. )Tj
T*
(J Clin Endocrinol Metab 1988;67:425-8.)Tj
-2.175 -1.25 Td
[(49.)-875 (MacGregor )54.8 (AJ, Dhillon )17.7 (VB, Binder )54.8 (A, et al. Fasting lipids and)]TJ
-0.00011 Tc 2.175 -1.25 Td
(anticardiolipin antibodies as risk factors for vascular disease in)Tj
0 Tc T*
[(systemic lupus erythematosus. )54.8 (Ann Rheum Dis 1992;51:152-5.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(50.)-875.1 (Richards GE, Grundy SM, Cooper K. Influence of plasma)]TJ
0 Tc 2.175 -1.25 Td
(triglycerides on lipoprotein patterns in normal subjects and in)Tj
T*
[(patients with coronary artery disease. )54.8 (Am J Cardiol 1989;)]TJ
0 Tw T*
(63:1214-20.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(51.)-875.1 (Davis CE, Gordon D, LaRosa J, )17.7 (W)79.7 (ood PD, Halperin M.)]TJ
0 Tc 2.175 -1.25 Td
(Correlations of plasma high-density lipoprotein cholesterol levels)Tj
T*
(with other plasma lipid and lipoprotein concentrations. Circulation)Tj
0 Tw T*
(1980;62:24-30.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(52.)-875.1 (Nossen JO, Rustan )54.8 (AC, Barnard )17.7 (T)73.9 (,)-0.1 ( Drevon CA. Inhibition by)]TJ
0 Tc 2.175 -1.25 Td
(chloroquine of the secretion of very low density lipoproteins by)Tj
T*
[(cultured rat hepatocytes. Biochim Biophys )54.9 (Acta 1984;803:1)36.9 (1-20.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(53.)-875.1 (Rustan )54.8 (AC, Nossen JO, )17.7 (T)69.7 (efre )17.7 (T)73.9 (, Drevon CA. Inhibition of very-)]TJ
0 Tc 2.175 -1.25 Td
(low-density lipoprotein secretion by chloroquine, verapamil, and)Tj
T*
[(monensin takes place in the Golgi complex. Biochim Biophys )54.9 (Acta)]TJ
0 Tw T*
[(1987;930:31)36.9 (1-9.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(54.)-875.1 (Goldstein JL, Brunschede GY)128.8 (, Brown MS. Inhibition of the)]TJ
0 Tc 2.175 -1.25 Td
(proteolytic degradation of the low density lipoprotein in human)Tj
T*
[(fibroblasts by chloroquine, concanavalin )54.9 (A, and )17.8 (T)34.9 (riton )17.8 (WR 1339.)]TJ
T*
(J Biol Chem 1975;250:7854-62.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(55.)-875.1 (Oram JF)79.7 (, )54.8 (Albers JJ, Cheung MC, Bierman EL. )17.7 (The ef)17.7 (fects of)]TJ
0 Tc 2.175 -1.25 Td
[(subfractions of high density lipoprotein on cholesterol ef)17.8 (flux from)]TJ
T*
(cultured fibroblasts. J Biol Chem 1981;256:8348-56.)Tj
-2.175 -1.25 Td
[(56.)-875 (Chen HW)91.8 (, Leonard DA. Chloroquine inhibits cyclization of)]TJ
2.175 -1.25 Td
(squalene oxide to lanosterol in mammalian cells. J Biol Chem)Tj
0 Tw T*
(1984;259:8156-62.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(57.)-875.1 (Borba EF)79.7 (, Bonf\341 E, )17.7 (V)60 (inagre CGC, Ramires JAF)79.7 (, Maranh\343o RC.)]TJ
0 Tc 2.175 -1.25 Td
(Chylomicron metabolism is markedly altered in systemic lupus)Tj
T*
[(erythematosus. )54.9 (Arthritis Rheum 2000;43:1033-40.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(58.)-875.1 (Bruce IN, Urowitz MB, Gladman DD, Hallett D. Natural history of)]TJ
0 Tc 2.175 -1.25 Td
(hypercholesterolemia in systemic lupus erythematosus. )Tj
T*
(J Rheumatol 1999;26:2137-43.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(59.)-875.1 (Ilowite NT)73.9 (. Premature atherosclerosis in systemic lupus)]TJ
0 Tc 2.175 -1.25 Td
(erythematosus. J Rheumatol 2000;27 Suppl 58:15-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(60.)-875.1 (Hallegua DS, )17.7 (W)79.7 (allace DJ. How accelerated atherosclerosis in SLE)]TJ
0 Tc 2.175 -1.25 Td
[(has changed our management of the disorder)54.9 (. Lupus 2000;)]TJ
0 Tw T*
(9:228-31.)Tj
ET
0 0 0 0 scn
465 777 92 -27 re
f*
468 770 90 -25 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/TT1 1 Tf
0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Borba and Bonf\341: Chlor)36.9 (oquine influence on SLE lipids)]TJ
0 Tw 61.4375 -0.0313 Td
(785)Tj
ET
0 0 0 0 scn
/GS0 gs
102.73 59.75 407.5 -10.83 re
f*
0.5 w
102.73 59.75 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
78 0 obj
<>
endobj
96 0 obj
<>
endobj
43 0 obj
<>
endobj
39 0 obj
<>
endobj
37 0 obj
<>
endobj
72 0 obj
<>stream
HVpMg}9ބ(ysHIn*ܨǽyh*Ȥ0ejWҥ֎mC갶MF*ztmcZtTYܳsT;?wV/ew ߧtTIExN@@)OoOW֯rZń(WŞ@